Fermeate raises US$2 million to bring light-controlled fermentation into existing bioreactors

Fermeate has raised a US$2 million Seed round to advance its light-controlled fermentation platform, as the industrial biotechnology startup looks to improve productivity inside existing biomanufacturing infrastructure.

• Fermeate has raised a US$2 million Seed round led by Newfund Capital, with participation from SOSV and other investors.
• The company’s optogenetic platform used light to regulate microbial activity during fermentation and improve production efficiency.
• Fermeate reported productivity improvements of 60% to 300% across industrial collaborations, depending on the organism and application.

The round was led by Newfund Capital, with participation from SOSV, Ajinomoto Group Ventures, Ki Tua Fund, Heuristic Capital Partners, Momentum Capital, Plug & Play, Tesserakt Ventures, and Ag Startup Engine.

Founded in 2024 by Kevin Xu and Saurabh Malani, Fermeate is developing optogenetic control systems for precision fermentation. The company’s technology used light-based genetic control to regulate microbial activity in real time during production, with the aim of increasing output without requiring major new capital investment in fermentation capacity.

Fermeate said the funding would support further development of its platform and help expand adoption across industrial partners in food, ingredients, and wider biomanufacturing. The company is targeting a persistent challenge for fermentation-based production: improving unit economics without relying only on larger reactors or new facilities.

Traditional industrial fermentation has often depended on scaling reactor capacity to reduce costs. Fermeate is pursuing a different route by targeting productivity gains within existing infrastructure. Its system used light as a signal to activate or deactivate metabolic pathways, allowing operators to adjust biological processes during production rather than relying only on fixed strain engineering.

According to the company, the platform has been designed to retrofit standard stainless-steel bioreactors with optogenetic control capabilities. Fermeate estimated the retrofit cost at under 5% of the investment required to install new fermentation capacity.

“Until now, the fermentation industry has largely relied on scale to reduce costs,” said Kevin Xu, CEO & Co-Founder of Fermeate. “We take a different approach, unlocking more outputs from existing reactors with minimal capital investment and a typical payback period of under 11 months based on third-party TEAs.”

The company said its platform combined optogenetic control with artificial intelligence models that helped identify which genes to target and when during fermentation cycles. Fermeate reported productivity improvements ranging from 60% to 300% in industrial collaborations, depending on the application and organism.

In some cases, the company said it had achieved up to a 200% increase in protein production within six months during partner deployments. Fermeate is currently working with four global food and ingredient companies, with early results showing measurable improvements within the first three months of implementation.

The company has also expanded compatibility across multiple microbial systems, including widely used industrial yeast and bacterial strains, as well as non-conventional hosts used in specialty fermentation processes.

Fermeate’s work is based on research originating from the Avalos Lab at Princeton University. The company is developing its technology as a potential enabling layer for industrial biomanufacturing, with applications across food production, specialty ingredients, and other fermentation-dependent sectors.

Investors in the round pointed to the platform’s focus on improving, rather than replacing, existing fermentation assets.

“Every major industrial transformation is built on a foundational infrastructure layer, and the bio-economy will be no exception,” said Henri Deshays, General Partner at Newfund Capital. “What makes Fermeate stand out is that their optogenetic platform upgrades the world’s existing fermentation capacity rather than replacing it - precisely the kind of horizontal, enabling technology Newfund has consistently backed.”

Fermeate said it would use the new capital to further scale its platform, expand industrial partnerships, and accelerate commercialization of its light-controlled fermentation systems.